BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 27, 2006
View Archived Issues
Millennium Makes $515M Offer For AnorMED, Tops Genzyme
Millennium Pharmaceuticals Inc. agreed to a $515 million premium purchase of AnorMED Inc., outbidding Genzyme Corp. for the Canadian biopharmaceutical firm and its Phase III cancer drug, Mozobil. (BioWorld Today)
Read More
Von Eschenbach: Strengthen FDA To Help Drug Discovery
Read More
Conditional Degron Opens Up Reversible Protein Knockouts
Read More
Arena, Merck Drop Pro-HDL Effort, But Drug's Still Alive
Read More
Immunicon's CellTracks Hits Endpoints In Cancer Study
Read More
Other News To Note
Read More
Clinic Roundup
Read More